ULS
$65.99-0.77%
as of close, Oct 2, 2026
☾ AH $65.99 -0.77%
ULS — UL Solutions Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDEDEDEDED
40.050.060.070.080.090.0100.0010.0M$65.99—202420252026
2026-10-02
Price$65.99
MA20$71.13
MA50$84.30
Vol1.2M
Key stats
Price data
- Price
- $65.99
- Change YTD
- -16.32%
- Next earnings
- Nov 3, 2026
- Market cap
- 13.3B
- Enterprise value
- 13.4B
- Shares outstanding
- 201.9M
- 52W low
- $63.17
- 52W high
- $107.54
- From 52W high
- -38.64%
- From 52W low
- +4.46%
- 52W range
- 6%
Volume
- Rel volume
- 1.39×
- 30D volume
- 839.3K
- 30D $ vol
- 57M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$2.1M
- Insider net 1Y
- −$11.1M
Form 4 transactions by trade date, as filed; latest on file 2026-09-01.
Fundamentals
- Sales (ttm)
- 3.1B
- Sales/share
- $15.58
- EPS (ttm)
- $2.48
- FCF (ttm)
- 436M
- FCF/share
- $2.16
- Book value/share
- $7.90
- Net margin
- 16.05%
- ROE
- 31.66%
- ROA
- 16.19%
- Debt / equity
- 0.19×
- Current ratio
- 1.42
Growth (CAGR, ttm) · 10Y
- Sales
- +6.61%+6.55%n/an/a
- Net income
- +54.48%+16.85%n/an/a
- FCF
- +19.80%+23.58%n/an/a
- Shares
- +0.51%+0.32%n/an/a
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +53.53%+16.16%n/an/a
- Sales/share
- +6.08%+6.26%n/an/a
- FCF/share
- +19.19%+23.24%n/an/a
- Book value/share
- +45.23%+10.37%n/an/a
- Dividend/share
- +7.85%-53.50%n/an/a
- Price
- -7.78%+29.33%n/an/a
- Total return
- -7.17%+30.42%n/an/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 26.6×
- Fwd P/E
- 24.8×
- P/S (ttm)
- 4.2×
- P/B (mrq)
- 8.4×
- P/FCF (ttm)
- 30.6×
- EV/EBITDA (fy)
- 17.8×
- EV/Sales (ttm)
- 4.3×
- FCF yield (ttm)
- 3.27%
- Dividend yield (fwd)
- 0.88%
- Dividend yield (ttm)
- 0.86%
- Dividend/share (fwd)
- $0.58
- Buyback yield (realized, 1y)
- -0.51%
- Shareholder yield (realized, 1y)
- 0.25%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.83%
Performance · price return · as of 2026-10-02
1D
-0.77%
5D
-0.09%
1M
-10.97%
3M
-31.96%
YTD
-16.32%
1Y
-7.77%
5Y
—
Recent filings
- Oct 18-K · Regulation FD disclosure
- Sep 1Insider sale · Scanlon Jennifer F. (President and CEO · Director) sold 12,500 Class A shares for $921K at $73.52–$74.43 under a 10b5-1 plan
- Aug 4Earnings · Earnings release — EPS $0.50 vs $0.52 est. (−3.9%); revenue $816.0M (+5% y/y) 14.0%
- Aug 4Report · Quarterly report, Q2 2026 — revenue $816.0M (+5% y/y), net income $246.0M, EPS $1.21
- Aug 3Insider sale · Scanlon Jennifer F. (President and CEO · Director) sold 12,500 Class A shares for $1.2M at $91.02–$92.89 under a 10b5-1 plan
Financial statements
Open full ULS financials →Loading financial statements…
Related Health Care
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| NVS | Novartis AG | -13.21% | -0.04% |
| NVO | Novo Nordisk A/S | -20.21% | -0.21% |
| SNY | Sanofi ADS | -10.23% | -1.84% |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | -6.76% | -0.32% |
| NTRA | Natera Inc. | +26.20% | +0.46% |
| ARGX | argenx SE American Depositary Shares | -12.90% | -1.79% |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | -3.09% | +0.00% |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | +5.44% | +0.56% |
